These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37557922)

  • 1. Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.
    Rezaei Z; Dastjerdi K; Allahyari A; ShahidSales S; Talebian S; Maharati A; Zangooie A; Zangouei AS; Sadri F; Sargazi S
    Toxicol Appl Pharmacol; 2023 Sep; 475():116652. PubMed ID: 37557922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
    Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
    DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.
    Normann LS; Aure MR; Leivonen SK; Haugen MH; Hongisto V; Kristensen VN; Mælandsmo GM; Sahlberg KK
    Sci Rep; 2021 May; 11(1):10893. PubMed ID: 34035375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
    Di Cosimo S; Appierto V; Pizzamiglio S; Silvestri M; Baselga J; Piccart M; Huober J; Izquierdo M; de la Pena L; Hilbers FS; de Azambuja E; Untch M; Pusztai L; Pritchard K; Nuciforo P; Vincent-Salomon A; Symmans F; Apolone G; de Braud FG; Iorio MV; Verderio P; Daidone MG
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab.
    Song W; Wu S; Wu Q; Zhou L; Yu L; Zhu B; Gong X
    J Cell Biochem; 2019 Aug; 120(8):14095-14106. PubMed ID: 31087707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
    Pizzamiglio S; Cosentino G; Ciniselli CM; De Cecco L; Cataldo A; Plantamura I; Triulzi T; El-Abed S; Wang Y; Bajji M; Nuciforo P; Huober J; Ellard SL; Rimm DL; Gombos A; Daidone MG; Verderio P; Tagliabue E; Di Cosimo S; Iorio MV
    Cancer Med; 2022 Jan; 11(2):332-339. PubMed ID: 34921525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
    Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
    Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
    Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
    Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.
    Pizzamiglio S; Ciniselli CM; de Azambuja E; Agbor-Tarh D; Moreno-Aspitia A; Suter TM; Trama A; De Santis MC; De Cecco L; Iorio MV; Silvestri M; Pruneri G; Verderio P; Di Cosimo S
    Breast Cancer Res Treat; 2024 Jul; 206(2):285-294. PubMed ID: 38689174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative bioinformatics analysis reveals miR-494 and its target genes as predictive biomarkers of trastuzumab-resistant breast cancer.
    Hermawan A; Putri H
    J Egypt Natl Canc Inst; 2020 Apr; 32(1):16. PubMed ID: 32372307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
    Giray BG; Emekdas G; Tezcan S; Ulger M; Serin MS; Sezgin O; Altintas E; Tiftik EN
    Mol Biol Rep; 2014 Jul; 41(7):4513-9. PubMed ID: 24595450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Circulating Mirnas Profiling for Identification of Potential Breast Cancer Early Detection Biomarkers.
    Jusoh AR; Mohan SV; Lu Ping T; Tengku Din TADAAB; Haron J; Romli RC; Jaafar H; Nafi SN; Tuan Salwani TI; Yahya MM
    Asian Pac J Cancer Prev; 2021 May; 22(5):1375-1381. PubMed ID: 34048164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
    Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
    Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2
    Decker JT; Hall MS; Blaisdell RB; Schwark K; Jeruss JS; Shea LD
    Biotechnol Bioeng; 2018 Oct; 115(10):2613-2623. PubMed ID: 29981261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of differential expression profile of miRNA in peripheral blood of patients with lung cancer.
    He Q; Fang Y; Lu F; Pan J; Wang L; Gong W; Fei F; Cui J; Zhong J; Hu R; Liang M; Fang L; Wang H; Yu M; Zhang ZF
    J Clin Lab Anal; 2019 Nov; 33(9):e23003. PubMed ID: 31541491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
    Noyan S; Gurdal H; Gur Dedeoglu B
    PLoS One; 2019; 14(4):e0215894. PubMed ID: 31009516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing
    Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J
    J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer.
    Zhu XL; Ren LF; Wang HP; Bai ZT; Zhang L; Meng WB; Zhu KX; Ding FH; Miao L; Yan J; Wang YP; Liu YQ; Zhou WC; Li X
    World J Gastroenterol; 2019 Apr; 25(13):1580-1591. PubMed ID: 30983818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.